Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13716530 | 0.92 | SOAT1 (0.36) | SOAT1 | |
| SCHEMBL13716632 | 0.91 | SOAT1 (0.35) | SOAT1 | |
| SCHEMBL13716586 | 0.91 | SOAT1 (0.35) | SOAT1 | |
| SCHEMBL13716597 | 0.90 | SOAT1 (0.35) | SOAT1 | |
| SCHEMBL9008269 | 0.79 | SOAT1 (0.39) | SOAT1 | |
| SCHEMBL9008076 | 0.75 | SOAT1 (0.36) | SOAT1KDM4E | |
| SCHEMBL9008152 | 0.75 | SOAT1 (0.36) | SOAT1KDM4E | |
| SCHEMBL9008128 | 0.75 | SOAT1 (0.36) | SOAT1 | |
| SCHEMBL9008115 | 0.74 | SOAT1 (0.39) | SOAT1CYP1A2 | |
| SCHEMBL9008139 | 0.74 | SOAT1 (0.35) | SOAT1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569590-B2 | Use of thianecarboxamides as dgat inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569590-B2 | Use of thianecarboxamides as dgat inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-04 | — | — | US | disclosed |
| US-20080090876-A1 | USE OF THIANECARBOXAMIDES AS DGAT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-17 | — | — | US | disclosed |
| US-20080090876-A1 | USE OF THIANECARBOXAMIDES AS DGAT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090876-A1 | USE OF THIANECARBOXAMIDES AS DGAT INHIBITORS | DGAT1, DGAT2, DLAT | SOAT1 7/4885KDM4E 2765/4885ALDH1A1 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.